Fate Therapeutics Inc

Fate Therapeutics is a biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's immuno-oncology product candidates inlcude: FATE-NK100 adaptive memory natural killer (NK) cell therapy, which is a NK cell cancer immunotherapy; and FT500 iPSC-derived NK cell product candidate, which is for the treatment of solid tumors, both as a monotherapy and in combination with checkpoint inhibitors. The company's immuno-regulation product candidates include: ProTmune?, which is used as an allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte?, which is for the treatment of autoimmune and inflammatory diseases.
  • TickerFATE
  • ISINUS31189P1021
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

David Nierengarten ...
  • Jeffrey La Rosa

FATE Moving Fast with FT500, Data Likely by YE19

David Nierengarten ...
  • Jeffrey La Rosa

FATE Moving Fast with FT500, Data Likely by YE19

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ValuEngine Rating and Forecast Report for FATE

ResearchPool Subscriptions

Get the most out of your insights

Get in touch